Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Colorcon
Julphar
Farmers Insurance
Chubb
QuintilesIMS
AstraZeneca
Cerilliant
Fish and Richardson

Generated: October 18, 2017

DrugPatentWatch Database Preview

Sun Pharma Global Company Profile

« Back to Dashboard

What is the competitive landscape for SUN PHARMA GLOBAL, and when can generic versions of SUN PHARMA GLOBAL drugs launch?

SUN PHARMA GLOBAL has seventy-two approved drugs.

There are three US patents protecting SUN PHARMA GLOBAL drugs. There are eight tentative approvals on SUN PHARMA GLOBAL drugs.

There are ninety-seven patent family members on SUN PHARMA GLOBAL drugs in forty-six countries and one hundred and forty-two supplementary protection certificates in thirteen countries.

Summary for Applicant: Sun Pharma Global

International Patents:97
US Patents:3
Tradenames:62
Ingredients:61
NDAs:72
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global
DESVENLAFAXINE
desvenlafaxine fumarate
TABLET, EXTENDED RELEASE;ORAL205583-002Jan 28, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Sun Pharma Global
DOCEFREZ
docetaxel
INJECTABLE;INJECTION022534-002May 3, 2011DISCNYesNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
DILTIAZEM HYDROCHLORIDE
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL090492-003Oct 28, 2011AB3RXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
NIACIN
niacin
TABLET, EXTENDED RELEASE;ORAL200484-001Apr 23, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
OXALIPLATIN
oxaliplatin
INJECTABLE;IV (INFUSION)202922-002Apr 8, 2014APRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
KETOROLAC TROMETHAMINE
ketorolac tromethamine
INJECTABLE;INJECTION078737-002Oct 6, 2008DISCNNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
MEMANTINE HYDROCHLORIDE
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205905-002Sep 28, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
ESZOPICLONE
eszopiclone
TABLET;ORAL091103-003Apr 3, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
doxorubicin hydrochloride
INJECTABLE, LIPOSOMAL;INJECTION203263-002Feb 4, 2013ABRXNoYes► Subscribe► Subscribe► Subscribe
Sun Pharma Global
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
cetirizine hydrochloride
TABLET, CHEWABLE;ORAL090142-004Aug 30, 2011OTCNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sun Pharma Global Drugs

Country Document Number Estimated Expiration
China101437800► Subscribe
Peru02922011► Subscribe
Costa Rica10399► Subscribe
Cuba20110055► Subscribe
Colombia6351744► Subscribe
Luxembourg92883► Subscribe
Spain2552347► Subscribe
EcuadorSP088860► Subscribe
Australia2007247860► Subscribe
South Africa200808962► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sun Pharma Global Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
883Luxembourg► SubscribePRODUCT NAME: SONIDEGIB OU UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE; FIRST REGISTRATION: 20150818
2014000071Germany► SubscribePRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
C0077France► SubscribePRODUCT NAME: SONIDEGIB OU SEL,HYDRATE,OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1030 20150818
2008013,C1412357Lithuania► SubscribePRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
60002Netherlands► SubscribePRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
00028Netherlands► SubscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
C/GB95/031United Kingdom► SubscribePRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026
172Luxembourg► SubscribePRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
2014 00048Denmark► SubscribePRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
11/016Ireland► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Julphar
Healthtrust
UBS
Medtronic
Dow
Deloitte
Harvard Business School
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot